Zymeworks INC 10-Q quarterly reports

Zymeworks Inc. reported a significant increase in Q3 2025 revenue driven by collaboration milestones and royalties, while advancing its wholly-owned oncology and AIID pipeline programs.

Zymeworks Inc. reported a significant increase in Q2 2025 revenue and a substantial reduction in net loss, driven by key milestone payments and initial royalties from its partnered zanidatamab program.

Zymeworks' Q1 2025 results show increased revenue driven by milestone payments and progress in clinical trials, alongside ongoing development of its wholly-owned pipeline.

Zymeworks reports a net loss of $99.2 million for the nine months ended September 30, 2024, while advancing its pipeline of novel biotherapeutics.

Zymeworks' Q2 2024 report details financial results, progress on zanidatamab, and advancements in early-stage pipeline programs.

Zymeworks reports a net loss of $31.7 million for the first quarter of 2024, with a decrease in revenue primarily due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.